Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward ... Read more.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5... Read more.
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the... Read more.
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical... Read more.
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis... Read more.
Apple Sued for Knowingly Hosting Child Sexual Abuse Material on Its Products, Failing to Protect Survivors
Landmark lawsuit brought on behalf of thousands of survivors of child sexual abuse images and videos (CSAM) traded on Apple platforms CUPERTINO, Calif., Dec. 8,... Read more.
Powering Canada’s Future: Ensuring Access to Affordable, Reliable and Clean Electricity in New Brunswick
DIEPPE, NB, Dec. 8, 2024 /CNW/ – In the 21st century, a reliable and affordable clean electricity grid is the backbone of a strong economy. Today more than... Read more.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based... Read more.
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
RIYADH, Saudi Arabia, Dec. 8, 2024 /PRNewswire/ — The role of governance in local, regional and international efforts to tackle land degradation, drought and... Read more.
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine... Read more.